Clinical Research Directory
Browse clinical research sites, groups, and studies.
sCD163 in HELLP Syndrome
Sponsor: Assiut University
Summary
Primary Aim: \_To investigate the diagnostic potential of soluble CD163 (sCD163)as a novel biomarker for the early detection of HELLP syndrome, assessing its sensitivity and specificity compared to current diagnostic markers. Secondary Aims: 1. To evaluate the correlation between sCD163 levels and the clinical severity of HELLP syndrome, including complications such as liver dysfunction, thrombocytopenia, and hemolysis. 2. To compare sCD163 levels across different stages of HELLP syndrome (partial vs. complete and other hypertensive disorders of pregnancy (e.g., preeclampsia).
Official title: The Significance of Soluble CD163 as a Novel Biomarker in the Early Detection and Severity Assessment of HELLP Syndrome
Key Details
Gender
FEMALE
Age Range
18 Years - 45 Years
Study Type
OBSERVATIONAL
Enrollment
70
Start Date
2025-12-01
Completion Date
2027-02
Last Updated
2025-10-07
Healthy Volunteers
Not specified
Conditions
Interventions
sCD163 level
The significance of soluble CD163 level in the early detection and severity assessment of HELLP Syndrome